Passage Bio Stock Alpha and Beta Analysis
| PASG Stock | USD 0.39 0 1.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Passage Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Passage Bio over a specified time horizon. Remember, high Passage Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Passage Bio's market risk premium analysis include:
Beta 1.45 | Alpha (0.47) | Risk 7.51 | Sharpe Ratio (0.10) | Expected Return (0.78) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Passage |
Passage Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Passage Bio market risk premium is the additional return an investor will receive from holding Passage Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Passage Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Passage Bio's performance over market.| α | -0.47 | β | 1.45 |
Passage Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Passage Bio's Buy-and-hold return. Our buy-and-hold chart shows how Passage Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Passage Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how Passage Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Passage Bio shares will generate the highest return on investment. By understating and applying Passage Bio stock market price indicators, traders can identify Passage Bio position entry and exit signals to maximize returns.
Passage Bio Return and Market Media
The median price of Passage Bio for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 0.6 with a coefficient of variation of 17.55. The daily time series for the period is distributed with a sample standard deviation of 0.11, arithmetic mean of 0.6, and mean deviation of 0.08. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 230321 shares by Orbimed Advisors Llc of Passage Bio at 0.6 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lynx1 Capital Management Lp of 373645 shares of Passage Bio at 0.6451 subject to Rule 16b-3 | 12/27/2024 |
3 | Disposition of 19481 shares by Orbimed Advisors Llc of Passage Bio at 0.77 subject to Rule 16b-3 | 01/06/2025 |
4 | Disposition of 52536 shares by Orbimed Advisors Llc of Passage Bio at 0.71 subject to Rule 16b-3 | 01/07/2025 |
5 | Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3 | 01/08/2025 |
6 | Disposition of 17986 shares by Orbimed Advisors Llc of Passage Bio at 0.64 subject to Rule 16b-3 | 01/13/2025 |
7 | Disposition of 79024 shares by Orbimed Advisors Llc of Passage Bio at 0.6 subject to Rule 16b-3 | 01/14/2025 |
8 | Insider Selling Passage Bio, Inc. Major Shareholder Sells 126,209 Shares of Stock | 01/15/2025 |
9 | Acquisition by Sondhi Dolan of 48000 shares of Passage Bio at 0.848 subject to Rule 16b-3 | 01/24/2025 |
10 | Acquisition by Sondhi Dolan of 092 shares of Passage Bio at 1.28 subject to Rule 16b-3 | 01/31/2025 |
11 | Acquisition by Chou William of 575000 shares of Passage Bio at 1.5 subject to Rule 16b-3 | 02/06/2025 |
12 | Disposition of 12500 shares by Fotopoulos Alexandros of Passage Bio subject to Rule 16b-3 | 02/07/2025 |
13 | Disposition of 8000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3 | 02/10/2025 |
14 | Disposition of 3183 shares by Kathleen Borthwick of Passage Bio at 0.5296 subject to Rule 16b-3 | 02/11/2025 |
15 | Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan | 02/26/2025 |
16 | Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights | 03/04/2025 |
17 | Acquisition by Cale Edgar B. of 50000 shares of Passage Bio subject to Rule 16b-3 | 03/07/2025 |
18 | Passage Bio stock plunges to 52-week low of 0.38 amid market challenges - Investing.com India | 03/13/2025 |
About Passage Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Passage or other stocks. Alpha measures the amount that position in Passage Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Passage Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Passage Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Passage Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Passage Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Passage Bio. Please utilize our Beneish M Score to check the likelihood of Passage Bio's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Passage Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Passage Bio Backtesting, Passage Bio Valuation, Passage Bio Correlation, Passage Bio Hype Analysis, Passage Bio Volatility, Passage Bio History and analyze Passage Bio Performance. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Passage Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.